HHGA
AGIO icon

Halbert Hargrove Global Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Halbert Hargrove Global Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-47
Closed -$1.89K – 376
2025
Q3 		$1.89K Buy
+47
New +$1.77K ﹤0.01% 576

Other funds holding AGIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Halbert Hargrove Global Advisors's AGIO Position: Q4 2025 in Review

Halbert Hargrove Global Advisors sold out of Agios Pharmaceuticals (AGIO) in Q4 2025, closing a stake of 47 shares — an estimated $1.89K sold.

Halbert Hargrove Global Advisors first reported a position in AGIO in Q3 2025 and held it in 1 quarter. The position peaked at $1.89K in Q3 2025. 238 funds tracked by Wall St. Rank hold AGIO as of Q4 2025.

  • Halbert Hargrove Global Advisors reported no remaining Agios Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Halbert Hargrove Global Advisors sold 47 Agios Pharmaceuticals shares in Q4 2025, an estimated $1.89K.
  • Halbert Hargrove Global Advisors first reported a position in Agios Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Halbert Hargrove Global Advisors's Agios Pharmaceuticals position peaked at $1.89K in Q3 2025.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2025.

Based on Halbert Hargrove Global Advisors's 13F filing for Q4 2025, filed 23 Jan 2026.